Loading clinical trials...
Loading clinical trials...
A Phase 3 Multicenter, Randomized, Open Label, Active-controlled, Study of AMG 510 Versus Docetaxel for the Treatment of Previously Treated Locally Advanced and Unresectable or Metastatic NSCLC Subjects With Mutated KRAS p.G12C
A Phase 3 Study to Compare AMG 510 with Docetaxel in Non Small Cell Lung Cancer (NSCLC) subjects with KRAS p. G12c mutation
Age
18 - 100 years
Sex
ALL
Healthy Volunteers
No
Pacific Cancer Medical Center Inc
Anaheim, California, United States
City of Hope National Medical Center
Duarte, California, United States
Pacific Shores Medical Group Long Beach
Long Beach, California, United States
University of California Los Angeles
Los Angeles, California, United States
University of California Los Angeles
Los Angeles, California, United States
University of California at Davis Medical Center
Sacramento, California, United States
Ridley Tree Cancer Center
Santa Barbara, California, United States
University of California San Francisco Mission Hall
Stanford, California, United States
Harbor University of California Los Angeles Medical Center
Torrance, California, United States
Rocky Mountain Cancer Centers
Denver, Colorado, United States
Start Date
June 4, 2020
Primary Completion Date
August 2, 2022
Completion Date
February 25, 2026
Last Updated
October 14, 2025
345
ACTUAL participants
AMG 510
DRUG
Docetaxel
DRUG
Lead Sponsor
Amgen
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions